Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR) is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (“CSU”) and Chronic Inducible Urticaria (“CIndU”), as well as diseases where targeting hemopoietic stem cells (“HSCs”) can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (“LR-MDS”), and novel stem cell transplant conditioning regimens. Jasper’s lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (“SCF”) from binding to and signaling through the CD117 receptor on mast and stem cells.